KRAS and colorectal carcinoma: Mutations within the PIK3CA gene [10], which is an important regulator of PI3K signaling, are also present in some CRC tumors that can co-occur with KRAS or BRAF mutations [8], [11], thus suggesting their possible influence on responsiveness to targeted therapeutics such as anti-EGFR antibodies but a clear demonstration of such a correlation is lacking [12], [13].